Everyone deserves the option of better mental health
Small Pharma is a biotechnology company researching and developing short-duration psychedelics with supportive therapy for mental health conditions.
Everyone deserves the option of better mental health
Small Pharma is a biotechnology company researching and developing short-duration psychedelics with therapy for under-served mental health conditions.
Today’s antidepressants leave a third of patients behind. This mental health epidemic needs solutions, not wishful thinking.
Peter Rands
Co-Founder, Small Pharma
We believe that everyone deserves the option of better mental health.
Millions of people suffer because the current standard of care is failing them. We want this to change. It's why we are on a mission to fast-track the development of novel, psychedelic-based treatments for patients suffering from mental health disorders.
Who we are,
what we do
Find out more about our story and meet the team behind Small Pharma
‘We do have to start looking for a completely different approach, and try something completely out of the box.’
Dr Carol Routledge, CMSO
Our approach
A novel approach to drug development, by innovating on known compounds to create new and protectable mental health treatments.
Our goal is to develop treatments that provide fast-acting relief, with long-lasting effects, that are scalable in-clinic treatments.
Our goal is to develop treatments that:
provide fast-acting relief
provide long-lasting effects
are scalable in-clinic
Our Approach
Accelerated drug development
We innovate on known compounds. This allows us to accelerate and reduce the risk of early drug development to ultimately speed up progress to trial potential medicines in human clinical trials.
Scalability
We focus on progressing therapies that have the potential to become scalable treatments in critical areas of unmet need, such as depression.
Fast-acting, long-lasting
Our goal is to develop optimized therapies for patients that target better outcomes than current treatments on offer, with rapid and durable relief.
Robust IP protection
We have a robust and multi-layered IP program to protect our innovation.
Our focus is short-duration psychedelics
Psychedelics with supportive therapy may have potential as antidepressant treatments.
Research to date has shown great potential with psychedelics in treating mental health conditions. Psychedelic compounds vary in their duration of subjective effects, often referred to as 'the psychedelic experience', which can range from minutes to more than 12 hours. We want to create scalable in-clinic mental health treatments, so we're focused on short-duration psychedelics with supportive therapy.
Research & trials
Years of R&D development
Treatments in development
Active clinical trials
Investor News
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
Results suggest SSRIs enhance the efficacy of SPL026 when administered to MDD patients on a…
Cybin to Acquire Small Pharma Inc.
Cybin to acquire Small Pharma creating an international clinical-stage leader in novel psychedelic therapeutics.
Small Pharma Reports Fiscal First Quarter 2024 Highlights
Financial highlights and recent business and R&D highlights.
